Abstract
The Institute for Clinical and Economic Review (ICER) previously proposed translating its ratings of comparative clinical effectiveness into the system of added benefit ratings used by Germany. This study compared ICER and German evidence ratings and explored which factors may explain any disagreement.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
